the global outlook on kratom
the importance of kratom remaining legal and accessible cannot be overstated
The United States has been seen as one of the main sources and examples for anti-drug policies around the world due to its economic and political influence through the 20-21st centuries. When there are any significant new policies launched by the US, many other countries have their internal policies significantly influenced by these decisions. One prime example of this was the prohibitive approach to cannabis during the 20th century.
The influence of the U.S. on these issues around the globe has been remarkable lately, especially when we have a closer look at cannabis’s medical uses and legalization. We have seen many countries follow their lead when it comes to legalization as well as decriminalization. When it comes to kratom, as its popularity has grown internationally, the rest of the world is paying attention. Any news and policies advocating for or against kratom in the United States will undoubtedly influence decisions globally.
Regarding the European Union, drug policies vary depending on the member states’ national legislation, but may be influenced by the the common strategy proposed by the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). The EMCDDA specifically mentions kratom among their drug profiles: “neither Mitragyna speciosa nor mitragynine or other alkaloids from the plant are listed in any of the Schedules of the United Nations Drug Conventions.”
Mitragyna speciosa and/or mitragynine and/or 7-hydroxymitragynine are currently (September 2011) controlled in a number of EU Member States such as Denmark, Latvia, Lithuania, Poland, Romania and Sweden.